Condition
Neuroendocrine Carcinoma of the Skin
Total Trials
4
Recruiting
0
Active
1
Completed
2
Success Rate
66.7%-20% vs avg
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 74/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
66.7%
-19.8% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results67% success
Data Visualizations
Phase Distribution
4Total
P 1 (1)
P 2 (3)
Trial Status
Completed2
Terminated1
Active Not Recruiting1
Trial Success Rate
66.7%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT04869137Phase 2Active Not Recruiting
Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma
NCT00002947Phase 1Terminated
Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer
NCT00004922Phase 2Completed
Irinotecan in Treating Patients With Advanced Neuroendocrine Tumors
NCT00003549Phase 2CompletedPrimary
S9716: Combination Chemotherapy in Treating Patients With Merkel Cell Cancer
Showing all 4 trials